BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laserna-Mendieta EJ, Casabona S, Savarino E, Perelló A, Pérez-Martínez I, Guagnozzi D, Barrio J, Guardiola A, Asensio T, de la Riva S, Ruiz-Ponce M, Rodríguez-Oballe JA, Santander C, Arias Á, Lucendo AJ; EUREOS EoE CONNECT research group. Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. Clin Gastroenterol Hepatol 2020;18:2903-2911.e4. [PMID: 31988045 DOI: 10.1016/j.cgh.2020.01.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 González-Cervera J, Arias Á, Navarro P, Juárez-Tosina R, Cobo-Palacios M, Olalla JM, Angueira-Lapeña T, Lucendo AJ. Tolerance to sterilised cow's milk in patients with eosinophilic oesophagitis triggered by milk. Aliment Pharmacol Ther 2022. [PMID: 35916162 DOI: 10.1111/apt.17171] [Reference Citation Analysis]
2 Facchin S, Calgaro M, Pandolfo M, Caldart F, Ghisa M, Vitulo N, Savarino EV. Editorial: non-invasive testing for EoE-does microbiome testing hold the key? Authors' reply. Aliment Pharmacol Ther 2022;56:729-30. [PMID: 35879893 DOI: 10.1111/apt.17144] [Reference Citation Analysis]
3 Lucendo AJ, Molina-Infante J. Current treatment options and long-term outcomes in patients with eosinophilic esophagitis. Expert Rev Clin Immunol 2022;:1-14. [PMID: 35770955 DOI: 10.1080/1744666X.2022.2096591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Muñoz FV, Almeida PH, Carrión-Jaramillo E, Montalvo AV. Clinical Features of Eosinophilic Esophagitis: A Single Center Experience in Ecuador. Pediatr Gastroenterol Hepatol Nutr 2022;25:293-9. [PMID: 35903492 DOI: 10.5223/pghn.2022.25.4.293] [Reference Citation Analysis]
5 Strauss AL, Falk GW. Refractory eosinophilic esophagitis: what to do when the patient has not responded to proton pump inhibitors, steroids and diet. Curr Opin Gastroenterol 2022;38:395-401. [PMID: 35762699 DOI: 10.1097/MOG.0000000000000842] [Reference Citation Analysis]
6 Turshudzhyan A, Samuel S, Tawfik A, Tadros M. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol 2022; 28(24): 2667-2679 [DOI: 10.3748/wjg.v28.i24.2667] [Reference Citation Analysis]
7 Navarro P, Laserna-Mendieta EJ, Casabona S, Savarino E, Pérez-Fernández MT, Ghisa M, Pérez-Martínez I, Guagnozzi D, Perelló A, Guardiola-Arévalo A, Racca F, Betoré E, Blas-Jhon L, Krarup AL, Martín-Domínguez V, Maniero D, Suárez A, Llerena-Castro R, de la Peña-Negro L, Navacerrada AG, Pellegatta G, Alcedo J, de Hurtado Mendoza-Guena L, Feo-Ortega S, Barrio J, Gutiérrez-Junquera C, Fernández-Fernández S, De la Riva S, E Navés J, Carrión S, Ciriza de Los Ríos C, García-Morales N, Rodríguez-Oballe JA, Dainese R, Rodríguez-Sánchez A, Masiques-Mas ML, Palomeque MT, Santander C, Tamarit-Sebastián S, Arias Á, Lucendo AJ. Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry. United European Gastroenterol J 2022. [PMID: 35578565 DOI: 10.1002/ueg2.12240] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Lucendo AJ. Drug treatment strategies for eosinophilic esophagitis in adults. Expert Opin Pharmacother 2022;:1-14. [PMID: 35379069 DOI: 10.1080/14656566.2022.2060077] [Reference Citation Analysis]
9 Główczewski A, Krogulska A. Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities. J Clin Med 2022;11:1454. [PMID: 35268544 DOI: 10.3390/jcm11051454] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lam AY, Ma C, Lee JK, Bredenoord AJ. Eosinophilic esophagitis: New molecules, better life? Curr Opin Pharmacol 2022;63:102183. [PMID: 35176546 DOI: 10.1016/j.coph.2022.102183] [Reference Citation Analysis]
11 Lucendo AJ, Santander C, Savarino E, Guagnozzi D, Pérez-martínez I, Perelló A, Guardiola-arévalo A, Barrio J, Elena Betoré-glaria M, Gutiérrez-junquera C, Ciriza de los Ríos C, Racca F, Fernández-fernández S, Blas-jhon L, Lund Krarup A, de la Riva S, Naves JE, Carrión S, Rodríguez Oballe JA, García-morales N, Tamarit-sebastián S, Navarro P, Arias Á, Laserna-mendieta EJ, Casabona-francés S, Pérez-fernández T, Llerena Castro R, Ghisa M, Manie D, Pellegatta G, Suárez A, Alcedo J, Gil Simón P, Teresa Palomeque M, Asensio T, Granja-navacerrada A, de Mendoza Guena LH, Rodríguez Sánchez A, Masiques Mas L, Dainese R, Feo-ortega S. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. Therap Adv Gastroenterol 2022;15:175628482210742. [DOI: 10.1177/17562848221074204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Tamarit-sebastian S, Ferrer-soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Feo-ortega S, Lucendo AJ. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Therap Adv Gastroenterol 2022;15:175628482110686. [DOI: 10.1177/17562848211068665] [Reference Citation Analysis]
14 Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, Paoletti G, Messina MR, Nappi E, Canonica GW, Repici A, Heffler E. Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets. Front Physiol 2022;12:815842. [DOI: 10.3389/fphys.2021.815842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 34550866 DOI: 10.1080/17474124.2021.1984878] [Reference Citation Analysis]
16 Oliva S, Dellon ES. Reversal of fibrosis in eosinophilic esophagitis: Another feather in the PPI cap? Dig Liver Dis 2021;53:1476-8. [PMID: 34531128 DOI: 10.1016/j.dld.2021.08.012] [Reference Citation Analysis]
17 Frandsen LT, Westmark S, Melgaard D, Krarup AL. Effectiveness of PPI treatment and guideline adherence in 236 patients with eosinophilic oesophagitis-Results from the population-based DanEoE cohort shows a low complication rate. United European Gastroenterol J 2021;9:910-8. [PMID: 34477326 DOI: 10.1002/ueg2.12146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Votto M, Raffaele A, De Filippo M, Caimmi S, Brunero M, Riccipetitoni G, Marseglia GL, Licari A. Eosinophilic gastrointestinal disorders in children and adolescents: A single-center experience. Dig Liver Dis 2021:S1590-8658(21)00341-8. [PMID: 34274254 DOI: 10.1016/j.dld.2021.06.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
19 Navarro P, Laserna-Mendieta EJ, Guagnozzi D, Casabona S, Perelló A, Savarino E, de la Riva S, Olalla JM, Ghisa M, Serrano-Moya N, Alcolea-Valero C, Ortega-Rabbione G, Majano P, Santander C, Arias Á, Lucendo AJ; EUREOS EoE CONNECT research group. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. Dig Liver Dis 2021:S1590-8658(21)00276-0. [PMID: 34120859 DOI: 10.1016/j.dld.2021.05.025] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
20 Biedermann L, Straumann A, Greuter T, Schreiner P. Eosinophilic esophagitis-established facts and new horizons. Semin Immunopathol 2021;43:319-35. [PMID: 34097125 DOI: 10.1007/s00281-021-00855-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Visaggi P, Mariani L, Pardi V, Rosi EM, Pugno C, Bellini M, Zingone F, Ghisa M, Marabotto E, Giannini EG, Savarino V, Marchi S, Savarino EV, de Bortoli N. Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. Nutrients 2021;13:1630. [PMID: 34066243 DOI: 10.3390/nu13051630] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
22 Odiase E, Zhang X, Chang Y, Nelson M, Balaji U, Gu J, Zhang Q, Pan Z, Spechler SJ, Souza RF. In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump. Gastroenterology 2021;160:2072-2088.e6. [PMID: 33581123 DOI: 10.1053/j.gastro.2021.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
23 Visaggi P, Savarino E, Sciume G, Chio TD, Bronzini F, Tolone S, Frazzoni M, Pugno C, Ghisa M, Bertani L, Bellini M, Savarino V, Peroni D, Marchi S, de Bortoli N. Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. Therap Adv Gastroenterol 2021;14:1756284820980860. [PMID: 33613690 DOI: 10.1177/1756284820980860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
24 Kim SJ, Park MI, Kim GH, Lee MW, Jung K, Lee J, Seol SY, Jee SR, Lee HS, Jang JS, Cha JH; Gyeongnam Society of Neurogastroenterology and Motility. Practice Patterns for Eosinophilic Esophagitis Patients in Busan and Gyeongnam: A Korean Multicenter Database Study. J Neurogastroenterol Motil 2021;27:71-7. [PMID: 32699187 DOI: 10.5056/jnm20069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Kanwal F. Issue Highlights. Clinical Gastroenterology and Hepatology 2020;18:2853-5. [DOI: 10.1016/j.cgh.2020.10.017] [Reference Citation Analysis]
26 Arias Á, Lucendo AJ. Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians. Expert Rev Gastroenterol Hepatol 2020;14:1069-82. [PMID: 32749898 DOI: 10.1080/17474124.2020.1806054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Lucendo AJ, Molina-infante J. Dietary therapy for eosinophilic esophagitis: chances and limitations in the clinical practice. Expert Review of Gastroenterology & Hepatology 2020;14:941-52. [DOI: 10.1080/17474124.2020.1791084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Savarino EV, Iovino P, Santonicola A, Ghisa M, Laserra G, Barberio B, Maniero D, Lorenzon G, Ciacci C, Savarino V, Zingone F. Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. J Clin Med 2020;9:E2011. [PMID: 32604895 DOI: 10.3390/jcm9062011] [Reference Citation Analysis]
29 Savarino EV, Iovino P, Santonicola A, Ghisa M, Laserra G, Barberio B, Maniero D, Lorenzon G, Ciacci C, Savarino V, Zingone F. Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. J Clin Med 2020;9:E2011. [PMID: 32604895 DOI: 10.3390/jcm9062011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
30 Reddy A, Ashat D, Murali AR. Recent insights on the use of topical steroids in eosinophilic esophagitis. Expert Rev Gastroenterol Hepatol 2020;14:953-63. [PMID: 32567417 DOI: 10.1080/17474124.2020.1785869] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Miehlke S, Lucendo AJ, Straumann A, Jan Bredenoord A, Attwood S. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. Therap Adv Gastroenterol 2020;13:1756284820927282. [PMID: 32565912 DOI: 10.1177/1756284820927282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]